相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij et al.
BLOOD (2012)
Sphingolipid Metabolism Cooperates with BAK and BAX to Promote the Mitochondrial Pathway of Apoptosis
Jerry E. Chipuk et al.
CELL (2012)
CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies
Jorge J. Castillo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies
Eric S. Winer et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
GCS overexpression is associated with multidrug resistance of human HCT-8 colon cancer cells
Min Song et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2012)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
Julia Hoellenriegel et al.
BLOOD (2011)
Ceramide and activated Bax act synergistically to permeabilize the mitochondrial outer membrane
Vidyaramanan Ganesan et al.
APOPTOSIS (2010)
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
Peter Dreger et al.
BLOOD (2010)
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
Sarah E. M. Herman et al.
BLOOD (2010)
Therapeutic applications of bioactive sphingolipids in hematological malignancies
Huseyin Atakan Ekiz et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity
Gareth Gerrard et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers
Rebecca L. Shaner et al.
JOURNAL OF LIPID RESEARCH (2009)
Bioactive sphingolipids: metabolism and function
Nana Bartke et al.
JOURNAL OF LIPID RESEARCH (2009)
Ceramide-induced cell death in malignant cells
Alexander Carpinteiro et al.
CANCER LETTERS (2008)
A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells
M. Vogler et al.
CELL DEATH AND DIFFERENTIATION (2008)
Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells
C. P. Pallasch et al.
LEUKEMIA (2008)
When do lasses (longevity assurance genes) become CerS (ceramide synthases)? Insights into the regulation of ceramide synthesis
Yael Pewzner-Jung et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia
D Heintel et al.
LEUKEMIA (2005)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells
A Petlickovski et al.
BLOOD (2005)
Acid sphingomyelinase is indispensable for UV light-induced bax conformational change at the mitochondrial membrane
H Kashkar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Biologically active sphingolipids in cancer pathogenesis and treatment
B Ogretmen et al.
NATURE REVIEWS CANCER (2004)
The complex life of simple sphingolipids
AH Futerman et al.
EMBO REPORTS (2004)
Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells
YY Liu et al.
JOURNAL OF LIPID RESEARCH (2004)
Role of the microenvironment in chronic lymphocytic leukaemia
F Caligaris-Cappio
BRITISH JOURNAL OF HAEMATOLOGY (2003)
BcR-induced apoptosis involves differential regulation of C16 and C24-ceramide formation and sphingolipid-dependent activation of the proteasome
BJ Kroesen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Induction of apoptosis through B-cell receptor cross-linking occurs via de novo generated C16-ceramide and involves mitochondria
BJ Kroesen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Targeting ceramide metabolism - a strategy for overcoming drug resistance
A Sanchenkov et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Ceramide glycosylation potentiates cellular multidrug resistance
YY Liu et al.
FASEB JOURNAL (2001)
Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance
YY Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
N-butyldeoxygalactonojirimycin:: A more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo
U Andersson et al.
BIOCHEMICAL PHARMACOLOGY (2000)
分享论文
